Home » Stocks » SVA

Sinovac Biotech Ltd. (SVA)

NASDAQ halted the trading of Sinovac stock in February, 2019.
Stock Price: $6.47 USD 0.00 (0.00%)
Updated Nov 3, 2020 4:00 PM EST

Stock Price Chart

Key Info

Market Cap 460.25M
Revenue (ttm) 246.05M
Net Income (ttm) 39.80M
Shares Out 71.14M
EPS (ttm) 0.28
PE Ratio 23.11
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Nov 3, 2020
Last Price $6.47
Previous Close $6.47
Change ($) 0.00
Change (%) 0.00%
Day's Open -
Day's Range 6.47 - 6.47
Day's Volume 0
52-Week Range 6.47 - 6.47

More Stats

Market Cap 460.25M
Enterprise Value 274.37M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 71.14M
Float 48.10M
EPS (basic) 0.42
EPS (diluted) 0.28
FCF / Share 0.30
Dividend n/a
Dividend Yield n/a
Earnings Yield 4.33%
FCF Yield 6.19%
Payout Ratio n/a
Shares Short 199,973
Short Ratio 0.00
Short % of Float 0.42%
Beta 0.10
PE Ratio 23.11
Forward PE n/a
P/FCF Ratio 16.17
PS Ratio 1.87
PB Ratio 1.82
Revenue 246.05M
Operating Income 68.56M
Net Income 39.80M
Free Cash Flow 28.47M
Net Cash 185.88M
Net Cash / Share 2.61
Gross Margin 94.97%
Operating Margin 27.86%
Profit Margin 16.20%
FCF Margin 11.57%
ROA 8.44%
ROE 16.95%
ROIC 25.80%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

Current: $6.47
Target: 6.00
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth7.14%31.72%140.71%7.44%7.12%-12.32%45.83%-13.42%70.18%-
Gross Profit21420515450.0449.0147.4651.2730.1235.7116.68
Operating Income68.5645.3245.420.503.701.899.95-21.153.37-13.36
Net Income44.9321.7825.81-0.60-1.42-1.527.44-14.85-0.84-8.51
Shares Outstanding94.8864.7357.0356.9556.3155.6855.3054.9354.6153.06
Earnings Per Share0.410.340.45-0.01-0.03-0.030.13-0.27-0.02-0.16
EPS Growth20.59%-24.44%--------
Operating Cash Flow39.077.9459.76-13.904.21-10.135.58-16.2513.94-14.28
Capital Expenditures-10.61-5.59-11.90-12.63-5.22-10.91-5.13-16.15-15.34-25.15
Free Cash Flow28.472.3547.86-26.53-1.01-21.040.44-32.41-1.40-39.43
Cash & Equivalents20617711665.4465.4691.2910791.24104103
Total Debt20.2713.9240.0743.0325.0051.7751.6937.7422.0320.49
Net Cash / Debt18616375.8922.4140.4639.5255.5653.5082.2582.60
Book Value294253151116122127129118130126
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Sinovac Biotech Ltd.
Country China
Employees 910
CEO Wei Dong Yin

Stock Information

Ticker Symbol SVA
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: SVA


Sinovac Biotech, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of vaccines against human infectious diseases in the People's Republic of China. The company's product portfolio includes vaccines against hepatitis A and B, enterovirus 71 (EV71), seasonal influenza, H5N1 and H1N1 pandemic influenza, and mumps, as well as hand, foot, and mouth diseases. Its marketed products include Healive, an inactivated hepatitis A vaccine; Bilive, a combined inactivated hepatitis A and B vaccine; Anflu, a split viron influenza vaccine; Panflu, a vaccine against the H5N1 influenza virus; Panflu.1, a vaccine against the influenza A H1N1 virus; mumps vaccine; split viron pandemic influenza vaccine; and Inlive, an EV71 vaccine. The company also completed phase III clinical trials for varicella, pneumococcal polysaccharide, and Sabin inactivated polio vaccines. Further, it is developing rubella vaccine; Sabin-strain inactivated polio vaccine; Sars-coVv-2 (COVID-19) vaccine; and quadrivalent influenza vaccine. Sinovac Biotech Ltd. has collaboration agreements with GlaxoSmithKline Biologicals SA to develop combination vaccines containing measles for the China market; Tianjin CanSino Biotechnology Inc. to develop a pneumococcal vaccine; Dynavax Technologies Corporation to develop a vaccine to prevent COVID-19; and Instituto Butantan to advance the clinical trials of CoronaVac, an inactivated vaccine candidate against COVID-19 to Phase III. The company was founded in 1999 and is based in Beijing, the People's Republic of China.